ArticleFrontiers in oncology2025
Predicting the prognosis of epithelial ovarian cancer patients based on deep learning models.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A prognostic model based on ScissorTranslational cancer research · 2026Article
- Outcomes and Long-term Follow-up of Epithelial Ovarian Cancer: Experience from the Lead Cancer Center of Pakistan.Journal of cancer & allied specialties · 2026Article
- Integrating multi-omics and clinical features to model survival in epithelial ovarian cancer subtypes.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epithelial ovarian cancer(EOC) has a higher mortality and morbidity rate than other types, and it has a dramatic impact on the survival of ovarian cancer(OC) patients. Therefore, investigating, developing and validating prognostic models to predict overall survival(OS) in patients with epithelial ovarian cancer represents an area of research with significant clinical implications. Methods: Patients with a confirmed diagnosis of epithelial ovarian cancer from 2010 to 2017 in The Surveillance, Epidemiology, and End Results(SEER) database were identified for enrollment based on inclusion and exclusion criteria(N=10902). Patients with epithelial ovarian cancer diagnosed from 2010 to 2022 were selected from Dalian Municipal Central Hospital as an external validation cohort based on the same criteria (N=116). COX proportional risk regression for screening independent prognostic factors. Survival outcomes were compared between different risk subgroups based on Kaplan-Meier analysis. Three predictive models were developed using machine learning(ML) techniques, and another was a nomogram based on COX proportional risk regression for estimating 3-year and 5-year overall survival in patients with epithelial ovarian cancer. Evaluation of several models based on multiple metrics including C-index, ROC curve, calibration curve and decision curve analysis (DCA). Results: Through univariate and multivariate COX proportional risk regression analyses, we selected 12 significantly independent prognostic factors affecting overall survival (P<0.05). In conclusion, comparing several models cited, it was found that DeepSurv (Deep Survival) model had the best performance in both internal validation set and external validation set. The C-index for internal validation was 0.715, and the 3-year and 5-year ROC curves were 0.746 and 0.766; the C-index for external validation was 0.672, and the 3-year and 5-year ROC curves were 0.731 and 0.756. Conclusion: This study successfully developed a nomogram and three machine learning models, which collectively served as important predictive instruments to support clinical decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.